European Society of Contraception Statement on Contraception in Obese Women

European Journal of Contraception and Reproductive Health Care

Volumn 20, Issue 1, 2015, Pages 19-28

  Merki Feld, Gabriele S ^a   Skouby, Sven ^b   Serfaty, David ^c   Lech, Medard ^d   Bitzer, Johannes ^e   Crosignani, Pier Giorgio ^f   Cagnacci, Angelo ^g   Sitruk Ware, Regine ^h  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Francophone Society of Contraception   (France)

^d Fertility and Sterility Research Center   (Poland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h POPULATION COUNCIL   (United States)

Author keywords

Contraceptive failure; Depo medroxyprogesterone; Efficacy; Hormonal contraception; Obesity; Progestin only contraception; Thromboembolic risk; Weight

Indexed keywords

CONTRACEPTIVE AGENT; DESOGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETONOGESTREL; GESTAGEN; METHYLPREDNISOLONE ACETATE;

ARTICLE; BARIATRIC SURGERY; CONTRACEPTION; DEVELOPED COUNTRY; DRUG EFFICACY; DRUG SAFETY; EMERGENCY CONTRACEPTION; EUROPE; HIGH RISK POPULATION; HORMONAL CONTRACEPTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MEDICAL SOCIETY; NONHUMAN; OBESITY; PREGNANCY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VENOUS THROMBOEMBOLISM; WORLD HEALTH ORGANIZATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; CONSENSUS DEVELOPMENT; FEMALE; METABOLISM; PROCEDURES;

CONTRACEPTION; CONTRACEPTION, POSTCOITAL; CONTRACEPTIVE AGENTS, FEMALE; DEVELOPED COUNTRIES; EUROPE; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; OBESITY; OVERWEIGHT; PREGNANCY; SOCIETIES, MEDICAL; VENOUS THROMBOEMBOLISM;

EID: 84921916001     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2014.960561     Document Type: Article

References (74)

1. Romp FR,le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: Obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139: 289-96.
2. Oliveros E, Somers V K, Sochor O, Goel K, Lopez-Jimenez F. The concept of normal weight obesity. Progr Cardiovasc Dis 2014; 56: 426-33.
3. The Centers for Disease control and Prevention. BMI categories. http://www. cdc. gov/nccdphp/dnpa/ healthweight. http://wwwcdcgov/nccdphp/dnpa/ healthweight. 2008.
4. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014.
5. Holt V L, Scholes D, Wicklund K G, Cushing-Haugen KL, Daling JR. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 2005; 105: 46-52.
6. Zieman M, G uillebaud J, W eisberg E, S hangold GA, Fisher AC, Creasy GW. Contraceptive effi cacy and cycle control with the Ortho Evra/Evra transdermal system: The analysis of pooled data. Fertil Steril 2002; 77: S13-18.
7. Burkman RT, Fisher AC, W an GJ, Barnowski CE, LaGuardia KD. Association between effi cacy and body weight or body mass index for two low-dose oral contraceptives. Contraception 2009; 79: 424-7.
8. Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U. S. cohort comparing progestogen and regimen. Obstet Gynecol 2011; 117: 33-40.
9. Westhoff C L, H ait H I, R eape K Z. B ody weight does not impact pregnancy rates during use of a low-dose extended-regimen 91-day oral contraceptive. Contraception 2012; 85: 235-9.
10. Trussell J, Guthrie KA, S chwarz EB. Much ado about little: Obesity, combined hormonal contraceptive use and venous thrombosis. Contraception 2008; 77: 143-6.
11. Lopez L M, Grimes D A, Chen M, et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev 2013; 4: CD008452.
12. Dragoman M, Petrie K, Torgal A, Thomas T, Cremers S, Westhoff CL. Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: A prospective study of normal BMI and obese women. Contraception 2013; 87: 432-6.
13. Westhoff C L, Torgal A H, M ayeda E R, et al. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. Am J Obstet Gynecol 2012; 207:39 e31-36.
14. Westhoff CL, Torgal AH, Mayeda ER, Pike MC, Stanczyk FZ. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception 2010; 81: 474-80.
15. Edelman AB, Cherala G, Munar M Y, et al. Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confi rms an altered pharmacokinetic profi le in obese oral contraceptives users. Contraception 2013; 87: 220-6.
16. E delman A B, Carlson N E, Cherala G, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception 2009; 80: 119-27.
17. Bonnema RA, Spencer AL. The new extended-cycle levonorgestrel-ethinyl estradiol oral contraceptives. Clin Med Insights Reprod Health 2011; 5: 49-54.
18. Anderson FD, Gibbons W, Portman D. Safety and effi-cacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 2006; 73: 229-34.
19. Nightingale A L, Lawrenson R A, Simpson E L, Williams TJ, MacRae KD, Farmer RD. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000; 5: 265-74.
20. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: A population-based cohort study. CMAJ 2011; 183: E1319-25.
21. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: Results of the MEGA case-control study. BMJ 2009; 339: b2921.
22. Parkin L, Sweetland S, Balkwill A, Green J, Reeves G, Beral V. Body mass index, surgery, and risk of venous thromboembolism in middle-aged women: A cohort study. Circulation 2012; 125: 1897-904.
23. Wattanakit K, Lutsey PL, Bell EJ, et al. Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A time-dependent analysis. Thromb Haemost 2012; 108: 508-15.
24. Parkin L, Sharples K, Hernandez R K, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested casecontrol study based on UK General Practice Research Database. BMJ 2011; 342: d2139.
25. Jick S S, Hernandez R K. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: Case-control study using United States claims data. BMJ 2011; 342: d2151.
26. Lidegaard O, Nielsen L H, Skovlund C W, Skjeldestad F E, Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011; 343: d6423.
27. Lidegaard O, Nielsen L H, Skovlund C W, Lokkegaard E. Venous thrombosis in users of non-oral hormonal contraception: Follow-up study, Denmark 2001-10. BMJ 2012; 344: e2990.
28. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: Final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007; 75: 344-354.
29. Dinger J, Bardenheuer K, Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenonecontaining combined oral contraceptives: Final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception 2014; 89: 253-63.
30. Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints. CHC-CVD fi nal report 111022v2. 2011.
31. Dinger J, Mohner S, Heinemann K. Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstet Gynecol 2013; 122: 800-08.
32. Shaw KA, Edelman A B. Obesity and oral contraceptives: A clinician ' s guide. Best Pract Res Clin Endocrinol Metab 2013; 27: 55-65.
33. Adams MR, Anthony MS, Manning JM, Golden DL, Parks JS. Low-dose contraceptive estrogen-progestin and coronary artery atherosclerosis of monkeys. Obstet Gynecol 2000; 96: 250-5.
34. Consensus conference on combination oral contraceptives and cardiovascular disease. Fertil Steril 1999; 71: 1S-6S.
35. Lidegaard O, Lokkegaard E, Jensen A, Skovlund C W, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366: 2257-66.
36. Kemmeren J M, Tanis B C, van den Bosch M A, et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: Oral contraceptives and the risk of ischemic stroke. Stroke 2002; 33: 1202-08.
37. Edelman AB, Jensen J T. Obesity and hormonal contraception: Safety and effi cacy. Semin Reprod Med 2012; 30: 479-85.
38. Koh SC, Singh K. The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fi brinolytic/inhibitor systems in women with menorrhagia. J Thromb Haemost 2007; 5: 133-8.
39. Bahamondes L, Petta C A, Fernandes A, Monteiro I. Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. Contraception 2007; 75: S134-9.
40. C heewadhanaraks S, C hoksuchat C, D hanaworavibul K, Liabsuetrakul T. Postoperative depot medroxyprogesterone acetate versus continuous oral contraceptive pills in the treatment of endometriosis-associated pain: A randomized comparative trial. Gynecol Obstet Invest 2012; 74: 151-6.
41. Merki-Feld G S, Imthurn B, Langner R, Sandor P S, Gantenbein AR. Headache frequency and intensity in female migraineurs using desogestrel-only contraception: A retrospective pilot diary study. Cephalalgia 2013; 33: 340-6.
42. Merki-Feld GS, Imthurn B, Seifert B, Merki LL, Agosti R, Gantenbein AR. Desogestrel-only contraception may reduce headache frequnecy and improve quality of life in female migraineurs. Eur J Contracept Reprod Health care 2013; 18: 394-400.
43. Nappi R E, Sances G, Allais G, et al. Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine wi th aura: A prospective diarybased pilot study. Contraception 2011; 83: 223-8.
44. Vickery Z, Madden T, Zhao Q, Secura GM, Allsworth JE, Peipert JF. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception 2013; 88: 503-08.
45. Lopez L M, Edelman A, Chen M, Otterness C, Trussell J, Helmerhorst FM. Progestin-only contraceptives: Effects on weight. Cochrane Database Syst Rev 2013; 7:C D008815.
46. Kivela A, Ruuskanen M, Agren U, Dieben T. The effects of two progrestogen-only pills containing either desogestrel (75 microgram/day) or levonorgestrel (30 microgram/day) on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care 2001; 6: 71-7.
47. Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. Contraception 2001; 64: 295-9.
48. Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol 2012; 120: 21-6.
49. Mornar S, Chan L N, Mistretta S, Neustadt A, Martins S, Gilliam M. Pharmacokinetics of the etonogestrel contraceptive implant in obese women. Am J Obstet Gynecol 2012; 207: 110 e111-6.
50. Diaz S, Pavez M, Moo-Young A J, Bardin CW, Croxatto HB. Clinical trial with 3-keto-desogestrel subdermal implants. Contraception 1991; 44: 393-408.
51. Ciangura C, Corigliano N, Basdevant A, et al. Etonorgestrel concentrations in morbidly obese women following Roux-en-Y gastric bypass surgery: Three case reports. Contraception 2011; 84: 649-51.
52. Urbancsek J. An integrated analysis of nonmenstrual adverse events with Implanon. Contraception 1998; 58: 109-15S.
53. Vicente L, Mendonca D, Dingle M, Duarte R, Boavida JM. Etonogestrel implant in women with diabetes mellitus. Eur J Contracept Reprod Health Care 2008; 13: 387-95.
54. Dilbaz B, Ozdegirmenci O, Caliskan E, Dilbaz S, Haberal A. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels. Contraception 2010; 81: 510-14.
55. Merki-Feld GS, Rosselli M, Imthurn B, Spanaus K. No effect of Implanon on infl ammatory cardiovascular parameters. Gynecol Endocrinol 2011; 27: 951-5.
56. Biswas A, Viegas O A, Roy A C. Effect of Implanon and Norplant subdermal contraceptive implants on serum lipids-a randomized comparative study. Contraception 2003; 68: 189-93.
57. Merki-Feld G S, Imthurn B, Rosselli M, Spanaus K. Implanon use lowers plasma concentrations of highmolecular-weight adiponectin. Fertil Steril 2011; 95: 23-7.
58. Fotherby K, Koetsawang S. Metabolism of injectable formulations of contraceptive steroids in obese and thin women. Contraception 1982; 26: 51-8.
59. Smit J, Botha J, McFadyen L, Beksinska M. Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval. Contraception 2004; 69: 3-7.
60. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive effi cacy and safety of DMPA-SC. Contraception 2004; 70: 269-75.
61. Jain J, Dutton C, Nicosia A, Wajszczuk C, Bode F R, Mishell DR, Jr. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception 2004; 70: 11-18.
62. Segall-Gutierrez P, T aylor D, L iu X, S tanzcyk F, Azen S, Mishell DR, Jr. Follicular development and ovulation in extremely obese women receiving depomedroxyprogesterone acetate subcutaneously. Contraception 2010; 81: 487-95.
63. Goldstein J, Cushman M, Badger G J, Johnson J V. Effect of depomedroxyprogesterone acetate on coagulation parameter: A pilot study. Fertil Steril 2007; 87: 1267-70.
64. van Hylckama Vlieg A, Helmerhorst F M, Rosendaal F R. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30: 2297-2300.
65. Segall-Gutierrez P, Xiang A H, Watanabe RM, et al. Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use. Contraception 2012; 85: 36-41.
66. Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012; 366: 1998-2007.
67. Seeber B, Ziehr SC, G schliebetaer A, et al. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel releasing intrauterine system. Contraception 2012; 86: 345-9.
68. Vilos GA, Marks J 68., Tureanu V, Abu-Rafea B, Vilos AG. The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleeding. J Minim Invasive Gynecol 2011; 18: 75-80.
69. Glasier A, Scorer J, Bigrigg A. Attitudes of women in Scotland to contraception: A qualitative study to explore the acceptability of long-acting methods. J Fam Plann Reprod Health Care 2008; 34: 213-17.
70. Glasier A F, Cameron S T, Fine P M, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: A randomised non-inferiority trial and meta-analysis. Lancet 2010; 375: 555-62.
71. Creinin MD, Schlaff W, Archer DF, et al. Progesterone receptor modulator for emergency contraception: A randomized controlled trial. Obstet Gynecol 2006; 108: 1089-97.
72. Brache V, Cochon L, Deniaud M, croxatto HB. Ulipristalacetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomised trials of emergency contraception regimens. Contraception 2013; 88: 611-18.
73. Glasier A, Cameron ST, Blithe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception 2011; 84: 363-7.
74. Paulen ME, Zapata LB, Cansino C, Curtis KM, Jamieson DJ. Contraceptive use among women with a history of bariatric surgery: A systematic review. Contraception 2010; 82: 86-94.